Immutep Announces First INSIGHT-004 Data and New TACTI-002 Data to be
Included in Poster Presentations During the ASCO 2020 Annual Meeting

On April 30, 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company") reported new data are scheduled to be presented in two poster presentations during the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper)’s (ASCO) (Free ASCO Whitepaper) Annual Meeting, a leading global scientific meeting for oncology professionals, taking place from 29 May – 31 May 2020 (Press release, Immutep, APR 30, 2020, View Source [SID1234556892]). This year ASCO (Free ASCO Whitepaper) is being held in a virtual format due to restrictions resulting from the COVID-19 pandemic. Abstracts and poster presentations will be published on the ASCO (Free ASCO Whitepaper) website (click here) at 8 a.m. ET on Friday, May 29, 2020. In addition, Immutep will make the data available on its website following its publication at ASCO (Free ASCO Whitepaper), at www.immutep.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentations at ASCO (Free ASCO Whitepaper)20 Virtual Scientific Program:

Title: Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab
Date: Available from 8 a.m. ET on Friday, MAY 29, 2020
Presenter: Dr. Enriqueta Felip, investigator
Abstract: 3100
Poster: 164
Title: Open-label, phase I study evaluating feasibility and safety of subcutaneous IMP321 (LAG-3Ig fusion protein, eftilagimod alpha) combined with avelumab in advanced stage solid tumor entities: results from stratum D of the INSIGHT platform trial
Date: Available from 8 a.m. ET on Friday, MAY 29, 2020
Presenter: PD. Dr. Thorsten O. Goetze, investigator
Abstract: 3099
Poster: 163
About TACTI-002

TACTI-002 is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as "MSD" outside the United States and Canada). It is evaluating the combination of efti with MSD’s KEYTRUDA (or pembrolizumab, an anti-PD-1 therapy) in up to 109 patients.

Immutep Limited, Level 12, 95 Pitt Street, Sydney NSW 2000

ABN: 90 009 237 889

About INSIGHT-004

INSIGHT-004 is the fourth arm of the investigator-initiated INSIGHT trial which is being conducted by Institute of Clinical Cancer Research, Krankenhaus Nordwest GmbH in Frankfurt, Germany (IKF). It is being conducted under Immutep’s collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer Inc., and is evaluating the safety, tolerability and recommended Phase II dose of Immutep’s lead immunotherapy product candidate efti when given in combination with avelumab in 12 patients with advanced solid malignancies.